GT Biopharma Inc (GTBP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.67M
Last updated: Nov 17, 2026 at 11:02 AM ET
GT Biopharma Inc (GTBP) Competitors
The companies most similar to GT Biopharma are In8bio (INAB), Tempest Therapeutics (TPST) and Theriva Biologics (TOVX). By market cap, GT Biopharma ranks 7th of the 13 companies on this page; Marker Therapeutics (MRKR) is the largest at $14.51M.
Peer Comparison
GTBP's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| GT Biopharma (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| In8bio Inc (INAB) | $8.86M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| FibroBiologics, Inc. Common Stock (FBLG) | $6.57M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| GRI Bio Inc. (GRI) | $3.72M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $7.83M | N/A | 15.5x | 0.0% | -101.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to GT Biopharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| In8bio Inc (INAB) | IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers... | INAB competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| FibroBiologics, Inc. Common Stock (FBLG) | FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology... | FBLG competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Intensity Therapeutics, Inc. Common stock (INTS) | Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. | INTS competitors |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
| GRI Bio Inc. (GRI) | GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. | GRI competitors |
Frequently Asked Questions About GTBP
Who are GT Biopharma's main competitors?
The companies most similar to GT Biopharma include In8bio (INAB), Tempest Therapeutics (TPST), Theriva Biologics (TOVX), Tscan Therapeutics (TCRX) and FibroBiologics, Inc. Common Stock (FBLG), listed from the closest match.
Who is GT Biopharma's biggest competitor?
Marker Therapeutics (MRKR) is the largest of the similar companies at $14.51M; In8bio (INAB) is the closest match by business profile, size, sector and industry.
How does GTBP stock compare with its competitors?
GTBP's net margin is 0.0% against a peer median of 0.0%.
Which of GT Biopharma's competitors pays a higher dividend?
GT Biopharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is GT Biopharma bigger than its competitors?
No. GT Biopharma is 7th by market cap among the 13 companies on this page; the largest is Marker Therapeutics (MRKR) at $14.51M.
GTBP pages: Overview, Earnings, Forecast, Financials, Competitors